Direct compression of veterinary tablets containing L-menthol crystalline API is constrained by needle-like particle habit, low bulk density, and a melting range of 41–44°C determined by the capillary method of Ph. Eur. 2.2.14. Identity is confirmed by infrared absorption spectrophotometry per Ph. Eur. 2.2.24 and optical rotation in a 10% w/v chloroform solution at 25°C per Ph. Eur. 2.2.7, with a limit between -49° and -51°. Feed material is screened through a conical mill fitted with a 0.5 mm rasp screen and round-edge impeller at 1,500–2,000 rpm, then pre-blended in a 1:20 geometric dilution with microcrystalline cellulose PH-102 and spray-dried lactose monohydrate in a bin blender at 12 rpm for 15 minutes. Blend homogeneity is measured by GC-FID according to Ph. Eur. 2.2.28 across 10 sampling locations; the acceptance limit is ≤ 5.0% relative standard deviation. Compression is performed on a rotary tablet press with 12 stations and a main compression force of 6–10 kN, producing tablets with hardness 60–90 N and friability ≤ 1.0% after 100 revolutions per Ph. Eur. 2.9.7. Disintegration is controlled by croscarmellose sodium at 2.0% w/w and sodium starch glycolate at 2.5% w/w; the specification is ≤ 15 minutes in 900 mL of 0.1 M HCl at 37°C using the basket apparatus of Ph. Eur. 2.9.3. Tablet cores are not dried above 40°C because measurable vapour pressure under forced air causes inter-batch loss of L-menthol and reduced assay. Excipients are pre-dried when relative humidity exceeds 60%, because surface free water mobilises water-soluble binders and increases capping at compression. Finished non-sterile oral dosage forms are tested for microbial quality per Ph. Eur. 2.6.12 and 2.6.13, with total aerobic microbial count ≤ 10³ CFU/g, total yeast and mould count ≤ 10² CFU/g, and absence of Escherichia coli in 1 g. Terminal packaging in cold-form aluminium blisters limits moisture ingress and sublimation from the tablet core.

What Limits Long-Term Physical Stability of L-Menthol in Multi-Dose Injectable Formulations?

L-menthol has reported aqueous solubility of 0.4–0.5 mg/mL at 25°C, requiring co-solvent systems for injectable veterinary compositions in cattle and swine. A representative vehicle comprises 30–50% v/v propylene glycol, 10–20% v/v ethanol, and water for injection to final volume, adjusted to pH 5.5–7.0 with citrate or phosphate buffer. The API is dissolved under low-shear mixing at 20–25°C, then filtered through a 0.22 µm PVDF membrane. Terminal moist-heat sterilisation at 121°C for 15 minutes requires retained-assay evaluation; L-menthol is steam-volatile, and headspace migration in sealed vials can reduce liquid-phase concentration by 2–8% depending on fill volume and headspace ratio. Aseptic filtration is preferred when steam sterilisation exceeds the assay tolerance. Nitrogen flushing to residual headspace oxygen ≤ 2.0% v/v reduces oxidative conversion to menthone and isomenthone. The solution is filled into Type I amber glass vials with PTFE-coated bromobutyl stoppers and stored below 25°C. Closure integrity is monitored by dye ingress using 0.1% methylene blue under 0.6 bar vacuum. Bacterial endotoxin content is controlled per Ph. Eur. 2.6.14 with a limit of ≤ 0.5 EU/mg for parenteral use in calves and pigs. Sterility is evaluated by direct inoculation according to Ph. Eur. 2.6.1. Multi-dose in-use stability is limited to 28 days after first puncture at 25°C/60% RH, with assay retention between 95.0% and 105.0%. Residual solvent compliance follows Ph. Eur. 5.4, with ethanol and propylene glycol controlled as specified for parenteral preparations.

Hard gelatin capsule filling with L-menthol requires conversion of crystalline API into an ordered mixture on a high-surface-area carrier. A typical carrier for veterinary capsule blends is anhydrous dibasic calcium phosphate or coprocessed silicified microcrystalline cellulose loaded at 5.0% w/w L-menthol relative to total fill weight. The pre-blend is passed through a 0.8 mm screen to break agglomerates and mixed in a low-shear V-blender at 25 rpm for 20 minutes. Colloidal silicon dioxide at 0.5% w/w is added as glidant before encapsulation on an intermittent-motion dosator or tamping-pin capsule filler. Content uniformity is tested according to Ph. Eur. 2.9.40, with an acceptance value not exceeding 15.0 for 10 individual capsules. Capsule shells are tested for disintegration in 900 mL of 0.1 M HCl at 37°C per Ph. Eur. 2.9.1, with complete disintegration ≤ 15 minutes. Because L-menthol can migrate into gelatin shells and cause localised softening in the body-joint region, storage at 25°C/60% RH in sealed aluminium-aluminium blisters is specified. High-density polyethylene bottles with desiccant canisters are acceptable when internal headspace moisture is calculated to remain below 1.5 g/day water vapour transmission. For medicated oral powders used as top-dress on calf milk replacer, L-menthol is diluted to an application strength of 0.5–2.0 g/kg finished feed with lactose monohydrate as the main diluent. Uniformity of the top-dress powder is measured across 10 samples taken from the top-dressed feed; relative standard deviation must be ≤ 10%. Particle size distribution is measured by laser diffraction and the D90 is controlled below 500 µm to prevent selective sorting. The powder specification includes loss on drying ≤ 0.5% after 4 hours at 50°C, sulphated ash ≤ 0.1% per Ph. Eur. 2.4.14, and absence of foreign matter by visual inspection of 25 g.

When L-Menthol Is Introduced into Pelleted Feed Premix Before Steam Conditioning

Addition of crystalline L-menthol to a feed premix before combined conditioning and pelleting creates a thermal loss interface controlled by conditioner retention time, moisture injection rate, and die temperature. Production-scale conditioner data show that uncoated crystalline L-menthol recovery after pelleting drops to 55–75% of the added amount at conditioner discharge temperatures of 70–80°C, while hydrogenated vegetable oil or maltodextrin-gum arabic microencapsulated grades retain 85–95% under the same conditions. The premix is prepared by serial dilution of microencapsulated L-menthol into ground maize or calcium carbonate carrier in a horizontal ribbon mixer; mixing time is 10–15 minutes at 50–60 rpm until blend homogeneity analysed by near-infrared reflectance or GC-FID is ≤ 5.0% relative standard deviation. Steam conditioning is operated with 1.5–2.0% added moisture and retention time of 30–60 seconds; the die hole length-to-diameter ratio is maintained at 8:1 to limit frictional temperature rise. Pellet temperature at the die outlet is recorded with an infrared sensor and should not exceed 85°C for unprotected L-menthol. Medicated feed homogeneity is evaluated according to Regulation (EU) 2019/4, with a coefficient of variation ≤ 10% for the incorporated veterinary medicinal substance across 10 incremental samples taken from mixer discharge or finished pellets. Carryover risk is managed by sequencing L-menthol-containing batches after high-volume flushing batches and by analysing rinsate from the conditioner wall and pellet die. Premix shelf life is assigned at 6 months at 25°C/60% RH for polymer-coated carriers; uncoated crystalline premix in non-barrier paper sacks may lose more than 10% of declared L-menthol within 3 months through sublimation.

Wet granulation of L-menthol into sachet or oral granules requires a hydroalcoholic binder to prevent crystal bloom. A binder solution of polyvinylpyrrolidone K30 at 3.0–5.0% w/w in 70:30 ethanol–water is sprayed onto a lactose monohydrate and maize starch base containing L-menthol at 1.0–3.0% w/w. Ethanol in the granulation fluid reduces L-menthol solubilisation and maintains discretely distributed crystals; water-only binder systems permit partial dissolution and subsequent needle-like recrystallisation on granule surfaces, increasing inter-granule variability. Granulation is conducted in a high-shear mixer with impeller speed 150–250 rpm and chopper speed 1,000–1,500 rpm; wet mass is discharged through an integrated wet mill fitted with a 2.5 mm screen. Drying is performed in a fluid-bed dryer with inlet air 40–45°C; higher inlet air temperatures cause L-menthol migration to the filter bag and yield loss. Residual ethanol is controlled by headspace GC and must be ≤ 0.5% w/w in the dried granules. Dried granules are milled through a 1.0 mm screen and size-classified; the fraction between 150 µm and 500 µm is filled into sachets. Flow is evaluated using a 25 mm orifice Hall flow funnel, with a typical flow rate of 10–20 g/s. Angle of repose is measured according to Ph. Eur. 2.9.36 with a limit of ≤ 35°. Friability of sachet granules is tested for 100 revolutions with a weight loss ≤ 1.0%. Assay per sachet is determined by GC-FID using Ph. Eur. 2.2.28; uniformity of 10 sachets must meet Ph. Eur. 2.9.40 with acceptance value ≤ 15.0. Storage in aluminium-laminated sachets at 25°C/60% RH protects against sublimation and caking.

Oral Drench Solutions and Drinking Water Medication Limits

Aqueous oral drench formulations for neonatal ruminants typically require L-menthol concentrations of 0.1–1.0% w/v with a co-solvent load adjusted for cold storage stability. Maximum solubility is achieved in a ternary system of purified water, glycerol, and polysorbate 80; glycerol at 20–30% v/v depresses L-menthol crystallisation at low storage temperatures, while polysorbate 80 at 5.0–10.0% w/v forms micellar associations with a cloud point above 80°C. Drench solutions are compounded in stainless steel tanks with bottom-mounted turbine agitation at 200–300 rpm for 30 minutes, then clarified through 1.0 µm depth filters. Product pH is adjusted with citric acid or sodium hydroxide to 4.5–6.5 to stabilise the API against alkaline oxidation; degradation to L-menthone is monitored by GC-MS with a specification of ≤ 2.0% total related substances. The drench is packed in HDPE jerry cans or PET bottles with induction-sealed closures; oxygen ingress is limited by specifying a maximum container oxygen transmission rate of 0.5 cm³/m²/day at 25°C. For drinking water medication, L-menthol is delivered as a water-soluble concentrate diluted at 1:500 to 1:2000 in drinking water for veal calves or weaned piglets. Medicated water concentration is checked by UV spectrophotometry at 205 nm, with a limit of ±10% of prescribed concentration in the first 6 hours. In hard water above 250 ppm CaCO₃, solutions may develop turbidity after standing; citric acid is pre-dissolved before L-menthol concentrate is added to prevent precipitation. Published data for the specific pharmacokinetic effect of water-administered L-menthol in all target species is limited; dose selection therefore requires veterinary prescription and monitoring of feed and water intake in the target group.